Copper fell along with other base metals as investors monitored the uncertainty surrounding US-Iran negotiations to possibly end the war. The US has insisted talks are ongoing while Iran has publicly rejected President Donald Trump’s outreach. The war, now nearing the one-month mark, has raised concerns about inflation and slowing industrial activity across the world, clouding the demand outlook f...
Copper fell along with other base metals as investors monitored the uncertainty surrounding US-Iran negotiations to possibly end the war. The US has insisted talks are ongoing while Iran has publicly rejected President Donald Trump’s outreach. The war, now nearing the one-month mark, has raised concerns about inflation and slowing industrial activity across the world, clouding the demand outlook for metals. Confusion over the direction and duration of the conflict is keeping some traders on the sidelines. “I have exited positions on base metals futures,” said Aces Zhou, a Shanghai-based trader at KS Commodities Ltd. “At this price level, I tend to wait for the geopolitical story to be done first and wait for another trading topic.” Still, investors are monitoring recovering demand in China after copper prices slipped 8% this month due to the Iran war. “It will be very comfortable for some fabricators to buy at current price level” as the country’s robust exports, especially of power equipment, drive demand, Zhou said. Copper on the London Metal Exchange fell 1.1% to $12,179 a ton as of 10:37 a.m. in Shanghai and aluminum declined 0.7%. Nickel steadied following a jump of 2.3% on Wednesday, after the world’s top producer Indonesia approved taxes on exports of the battery metal.
Earnings Call Insights: Journey Medical Corporation (DERM) Q4 2025 Management View Claude Maraoui, Founder, President, CEO & Director, described 2025 as a milestone year, highlighting the successful launch of Emrosi, Journey’s internally developed oral rosacea treatment. "Emrosi was made available to pharmacies in late March of last year, and our promotional activities began in early April. I am p...
Earnings Call Insights: Journey Medical Corporation (DERM) Q4 2025 Management View Claude Maraoui, Founder, President, CEO & Director, described 2025 as a milestone year, highlighting the successful launch of Emrosi, Journey’s internally developed oral rosacea treatment. "Emrosi was made available to pharmacies in late March of last year, and our promotional activities began in early April. I am pleased to report that during the 3 quarters of 2025 in which Emrosi was commercially available, the product achieved $14.7 million in net sales." Maraoui reported, "We delivered total net product revenue growth of 11%, and we improved our gross margin by nearly 3.5 percentage points compared to the 2024 period. Importantly, our business was able to make solid financial progress despite pressure on our Accutane franchise and other legacy products due to generic competition." The company recorded positive adjusted EBITDA as well as positive EBITDA in Q4 2025 and expects to remain adjusted EBITDA positive in 2026 and beyond. Maraoui stated, "With our solid cash position of approximately $24 million, I believe that Journey is well positioned to execute on our business plan and grow sales and profitability with the resources that we have in place." Prescription volume for Emrosi grew nearly 50% sequentially in Q4 versus Q3, with over 3,500 unique dermatology prescribers having written at least one script for Emrosi by year end. Maraoui noted, "At present, approximately 100 million commercial covered lives have access to Emrosi. This includes contracts in place with 2 of the top 3 group purchasing organizations in the United States." Plans to launch one or two incremental dermatology products later in 2026 were announced. Joseph Benesch, CFO, stated, "Total revenues for the year were $61.9 million, representing a 10% increase compared to $56.1 million for 2024. The increase reflects incremental net product revenue related to the successful U.S. commercial launch of Emrosi." Outlo...
Nvidia-backed startup Reflection AI is in talks to raise $2.5 billion at a valuation of $25 billion, the Wall Street Journal reported on Wednesday, citing people familiar with the matter. Here are some details:
Nvidia-backed startup Reflection AI is in talks to raise $2.5 billion at a valuation of $25 billion, the Wall Street Journal reported on Wednesday, citing people familiar with the matter. Here are some details: